New BARDA award: Ortho Clinical Diagnostics null
Post# of 36536
(Total Views: 300)
Posted On: 06/17/2020 5:28:30 PM
New BARDA award: Ortho Clinical Diagnostics null
Product Name: VITROS® Anti-SARS-CoV-2 Total Test
View Announcement
Description:
High-accuracy immunoassay for the qualitative detection of total (IgG, IgM, IgA, and other) antibodies to SARS-CoV-2 – offered on random-access, high throughout laboratory instruments. One award of $678,000 is funding continued development of this assay and the Ortho IgG test.
Unique Impact:
This immunoassay can be used to assess immune response for aiding in the diagnosis of COVID-19 infection, assessing seroprevalence, and for identifying who can donate convalescent plasma. It is offered on high-throughput laboratory instruments that do not require plumbing, for the greatest workflow advantages.
Status: EUA Issued
Award Amount: $678,000.00
Product Name: VITROS® Anti-SARS-CoV-2 Total Test
View Announcement
Description:
High-accuracy immunoassay for the qualitative detection of total (IgG, IgM, IgA, and other) antibodies to SARS-CoV-2 – offered on random-access, high throughout laboratory instruments. One award of $678,000 is funding continued development of this assay and the Ortho IgG test.
Unique Impact:
This immunoassay can be used to assess immune response for aiding in the diagnosis of COVID-19 infection, assessing seroprevalence, and for identifying who can donate convalescent plasma. It is offered on high-throughput laboratory instruments that do not require plumbing, for the greatest workflow advantages.
Status: EUA Issued
Award Amount: $678,000.00
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼